• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HER2 阳性棘层松解性鳞状细胞乳腺癌的新辅助治疗：一例报告。

Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report.

机构信息

Department of Breast Surgery, Dalian Women and Children's Medical Group, Dalian, People's Republic of China.

Department of Breast Surgery, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.

出版信息

J Int Med Res. 2023 Aug;51(8):3000605231187936. doi: 10.1177/03000605231187936.

DOI:10.1177/03000605231187936
PMID:37534455
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10566270/
Abstract

HER2-positive acantholytic squamous cell carcinoma (ASCC) of the breast is exceptionally rare, and its clinicopathologic features are poorly understood. The impact of neoadjuvant therapy on HER2-positive breast ASCC is unclear. Here we report on a 58-year-old woman who was diagnosed with HER2-positive ASCC of the right breast, who underwent neoadjuvant treatment with albumin-paclitaxel, carboplatin, and trastuzumab, and surgery. Neoadjuvant therapy was effective, with no recurrence or metastasis after 1.5 years of postoperative follow-up.

摘要

HER2 阳性棘层松解性鳞状细胞癌（ASCC）极为罕见，其临床病理特征尚未完全明确。新辅助治疗对 HER2 阳性乳腺 ASCC 的影响尚不清楚。本文报道了 1 例 58 岁女性，右乳 HER2 阳性 ASCC，接受白蛋白紫杉醇、卡铂和曲妥珠单抗新辅助治疗及手术治疗。新辅助治疗有效，术后 1.5 年随访无复发或转移。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/10566270/7c2d67ee543b/10.1177_03000605231187936-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/10566270/e1f16f1b8e9d/10.1177_03000605231187936-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/10566270/540c6027eb4f/10.1177_03000605231187936-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/10566270/b1f749d3d6ed/10.1177_03000605231187936-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/10566270/7c2d67ee543b/10.1177_03000605231187936-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/10566270/e1f16f1b8e9d/10.1177_03000605231187936-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/10566270/540c6027eb4f/10.1177_03000605231187936-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/10566270/b1f749d3d6ed/10.1177_03000605231187936-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/10566270/7c2d67ee543b/10.1177_03000605231187936-fig4.jpg

相似文献

1
Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report.HER2 阳性棘层松解性鳞状细胞乳腺癌的新辅助治疗：一例报告。
J Int Med Res. 2023 Aug;51(8):3000605231187936. doi: 10.1177/03000605231187936.
2
Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.每周使用紫杉醇联合卡铂，联合或不联合曲妥珠单抗作为HER2阳性乳腺癌的新辅助化疗：HER2扩增的缺失及其对反应和预后的影响。
Breast Cancer Res Treat. 2017 Jan;161(2):259-267. doi: 10.1007/s10549-016-4064-9. Epub 2016 Nov 24.
3
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.曲妥珠单抗、帕妥珠单抗和化疗新辅助治疗与曲妥珠单抗恩美曲妥珠单抗和帕妥珠单抗联合用于 HER2 阳性乳腺癌患者（KRISTINE）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.
4
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.Ⅱ期研究：新辅助每周紫杉醇联合白蛋白结合型紫杉醇和卡铂，联合贝伐珠单抗和曲妥珠单抗，用于治疗局部晚期 HER2+ 乳腺癌女性患者。
Clin Breast Cancer. 2011 Oct;11(5):297-305. doi: 10.1016/j.clbc.2011.04.002. Epub 2011 May 5.
5
Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.ABP 980 对比参照曲妥珠单抗用于治疗人表皮生长因子受体 2（HER2）阳性早期乳腺癌女性患者的疗效和安全性：一项随机、双盲、III 期临床试验（LILAC 研究）
Lancet Oncol. 2018 Jul;19(7):987-998. doi: 10.1016/S1470-2045(18)30241-9. Epub 2018 Jun 4.
6
Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.术前使用曲妥珠单抗和化疗治疗HER2过表达乳腺癌后的长期随访
Clin Breast Cancer. 2015 Feb;15(1):24-30. doi: 10.1016/j.clbc.2014.07.010. Epub 2014 Aug 15.
7
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.曲妥珠单抗新辅助化疗联合辅助曲妥珠单抗与单纯新辅助化疗治疗人表皮生长因子受体 2 阳性局部晚期乳腺癌患者（NOAH 试验）：一项具有平行人表皮生长因子受体 2 阴性队列的随机对照优效性试验。
Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.
8
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.曲妥珠单抗辅助治疗局部晚期或炎性乳腺癌的 NeOAdjuvant Herceptin（NOAH）研究中，接受新辅助治疗后行手术治疗的 HER2 阳性患者。
Eur J Surg Oncol. 2011 Oct;37(10):856-63. doi: 10.1016/j.ejso.2011.07.003. Epub 2011 Aug 16.
9
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.体细胞PI3K通路和ERBB家族突变对接受新辅助HER2靶向治疗的HER2阳性乳腺癌患者病理完全缓解（pCR）的影响。
Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.
10
[A Case of Metaplastic Squamous Cell Carcinoma of the Breast Diagnosed after Neoadjuvant Chemotherapy].[1例新辅助化疗后诊断的乳腺化生性鳞状细胞癌病例]
Gan To Kagaku Ryoho. 2018 Jul;45(7):1101-1103.

引用本文的文献

1
A rare case of HER2-positive pure metaplastic squamous cell carcinoma of the breast.1例罕见的HER2阳性乳腺纯化生鳞状细胞癌。
Discov Oncol. 2025 Jul 16;16(1):1340. doi: 10.1007/s12672-025-03107-9.

本文引用的文献

1
Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast.1例HER2阳性乳腺鳞状细胞癌患者对新辅助化疗的病理完全缓解
Case Rep Oncol. 2021 Oct 22;14(3):1536-1541. doi: 10.1159/000519746. eCollection 2021 Sep-Dec.
2
Clinicopathological Characteristics and Prognosis of Squamous Cell Carcinoma of the Breast: A Population-Based Analysis.基于人群的分析：乳腺鳞状细胞癌的临床病理特征和预后。
Cancer Control. 2021 Jan-Dec;28:10732748211044355. doi: 10.1177/10732748211044355.
3
Adenoid (Acantholytic) Squamous Cell Carcinoma of Mandibular Gingiva.
下颌牙龈腺样（棘层松解性）鳞状细胞癌
Case Rep Dent. 2021 Jul 22;2021:5570092. doi: 10.1155/2021/5570092. eCollection 2021.
4
A rare acantholytic variant of squamous cell carcinoma of the maxilla: A case report and literature review.上颌骨鳞状细胞癌的一种罕见棘层松解变异型：病例报告及文献综述
Medicine (Baltimore). 2020 Aug 7;99(32):e21631. doi: 10.1097/MD.0000000000021631.
5
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.与曲妥珠单抗为基础的新辅助化疗治疗人表皮生长因子受体 2 阳性乳腺癌疗效相关的临床病理因素。
Clin Breast Cancer. 2020 Feb;20(1):19-24. doi: 10.1016/j.clbc.2019.09.003. Epub 2019 Sep 18.
6
Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis.乳腺鳞状细胞癌的临床病理特征、治疗模式和预后：NCDB 分析。
BMC Cancer. 2019 Jan 8;19(1):26. doi: 10.1186/s12885-018-5212-x.
7
A Case of Acantholytic Squamous Cell Carcinoma.棘层松解性鳞状细胞癌一例。
Ann Dermatol. 2008 Dec;20(4):267-70. doi: 10.5021/ad.2008.20.4.267. Epub 2008 Dec 31.
8
Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?磁共振检查预测新辅助化疗后的病理完全缓解：HER2阳性和三阴性乳腺癌何时适用？
Breast Cancer. 2016 Sep;23(5):789-96. doi: 10.1007/s12282-015-0642-7. Epub 2015 Oct 5.
9
Acantholytic squamous cell carcinoma of the oral cavity: A rare entity.口腔棘层松解性鳞状细胞癌：一种罕见的实体。
J Oral Maxillofac Pathol. 2014 Sep;18(Suppl 1):S128-30. doi: 10.4103/0973-029X.141359.
10
Acantholytic squamous cell carcinoma: pathological study of nine cases with review of literature.棘层松解性鳞状细胞癌：9例病理研究并文献复习
Rom J Morphol Embryol. 2014;55(2):279-83.